Intensity Therapeutics, Inc.
INTSHealthcare|Biotechnology|US
$3.00
-0.10 (-3.23%)
DCF Value
$8.35
Tangible Book / Share
$2.35
Cash / Share
$2.61
Financials
Financial Snapshot
Market Cap
$8.1M
Enterprise Value
-$298.5K
Revenue (TTM)
$0.00
Net Income (TTM)
-$12.0M
Cash & Investments
$8.5M
Net Cash
$8.4M
Free Cash Flow (TTM)
-$9.1M
Operating CF (TTM)
-$9.1M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$8.5M
Quarterly Burn
$2.3M
Monthly Burn
$755.6K
Est. Runway
~3.7 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $8.4M | $9.3M | $4.5M | $1.3M | $14.8M | $2.6M | $11.9M | $8.5M | |
| Operating Cash Flow | -$4.4M | -$5.4M | -$6.8M | -$5.5M | -$7.2M | -$15.2M | -$9.2M | -$9.1M | |
| Free Cash Flow | -$4.4M | -$5.4M | -$6.8M | -$5.5M | -$7.2M | -$15.2M | -$9.2M | -$9.1M | |
| Capital Expenditure | $0.00 | $0.00 | $3.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $3.9M | $6.3M | $2.0M | $2.3M | $20.5M | $2.9M | $18.6M | $10.5M |
R&D Spending
R&D (TTM)
$7.0M
R&D Intensity
—
R&D Growth vs Prior
+2.6%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $4.4M | $5.1M | $5.9M | $5.1M | $4.8M | $10.5M | $6.8M | $7.0M | |
| SG&A | $1.2M | $1.2M | $2.1M | $2.4M | $3.4M | $6.1M | $5.2M | $5.4M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $147.0K | $0.00 | $26.0K | $14.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | -$147.0K | $0.00 | -$26.0K | -$14.0K | |
| R&D | $4.4M | $5.1M | $5.9M | $5.1M | $4.8M | $10.5M | $6.8M | $7.0M | |
| SG&A | $1.2M | $1.2M | $2.1M | $2.4M | $3.4M | $6.1M | $5.2M | $5.4M | |
| Operating Income | -$5.7M | -$6.2M | -$8.0M | -$7.5M | -$8.3M | -$16.6M | -$12.0M | -$12.4M | |
| Interest Expense | $0.00 | $0.00 | $16.8K | $81.8K | $305.0K | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$5.4M | -$6.0M | -$7.9M | -$7.6M | -$10.5M | -$16.3M | -$11.6M | -$12.0M | |
| Net Income | -$5.2M | -$6.0M | -$7.9M | -$7.6M | -$10.5M | -$16.3M | -$11.6M | -$12.0M | |
| EPS (Diluted) | -39.50 | -44.25 | -58.00 | -55.50 | -34.50 | -29.25 | -8.56 | -4.37 | |
| EBITDA | $295.7K | -$6.0M | -$7.9M | -$7.3M | -$10.1M | -$16.3M | -$11.6M | -$12.2M | |
| Shares Out. (M) | 0.14 | 0.14 | 0.14 | 0.14 | 0.34 | 0.56 | 1.36 | 3.26 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.8M | $9.3M | $4.5M | $1.3M | $8.6M | $2.6M | $11.9M | $8.5M | |
| Short-Term Investments | $4.6M | $0.00 | $0.00 | $0.00 | $6.2M | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $8.6M | $9.5M | $4.7M | $1.5M | $15.5M | $3.4M | $12.7M | $9.5M | |
| Total Assets | $9.0M | $10.1M | $5.2M | $1.8M | $17.3M | $4.8M | $14.1M | $10.3M | |
| Total Current Liabilities | $1.1M | $1.3M | $3.7M | $6.8M | $4.0M | $1.8M | $2.1M | $2.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $79.0K | $0.00 | |
| Total Liabilities | $1.3M | $11.7M | $13.9M | $16.9M | $4.1M | $1.9M | $2.2M | $2.6M | |
| Stockholders' Equity | $7.7M | -$1.6M | -$8.7M | -$15.1M | $13.2M | $2.9M | $11.9M | $7.7M | |
| Retained Earnings | $0.00 | -$23.2M | -$31.1M | -$38.7M | -$50.5M | -$66.8M | -$78.4M | -$87.4M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.4M | -$5.4M | -$6.8M | -$5.5M | -$7.2M | -$15.2M | -$9.2M | -$9.1M | |
| Capital Expenditure | $0.00 | $0.00 | $3.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$4.4M | -$5.4M | -$6.8M | -$5.5M | -$7.2M | -$15.2M | -$9.2M | -$9.1M | |
| Investing Cash Flow | $1.7M | $4.6M | $0.00 | $0.00 | -$6.0M | $6.4M | $0.00 | $0.00 | |
| Financing Cash Flow | $3.9M | $6.3M | $2.0M | $2.3M | $20.5M | $2.9M | $18.6M | $10.5M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $22.4M | $3.2M | $18.6M | $10.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$60.0K | |
| Net Debt Issuance | $0.00 | $0.00 | $2.0M | $2.3M | $230.0K | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $561.4K | $555.5K | $719.8K | $1.2M | $1.4M | $3.1M | $2.0M | $1.7M | |
| Net Change in Cash | $1.1M | $5.5M | -$4.8M | -$3.2M | $7.2M | -$6.0M | $9.3M | $1.4M |
Dilution Tracker
Shares outstanding grew 894.5% over 5 years — significant dilution
Shares Outstanding
3M
5-Year Share Growth
+894.5%
Stock Issuance (TTM)
$10.6M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.14 | 0.14 | 0.14 | 0.14 | 0.34 | 0.56 | 1.36 | 3.26 | |
| Change vs Prior % | — | 0.2% | 0.0% | 0.0% | 152.7% | 61.4% | 143.8% | 140.1% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $22.4M | $3.2M | $18.6M | $10.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$60.0K | |
| Stock Based Comp. | $561.4K | $555.5K | $719.8K | $1.2M | $1.4M | $3.1M | $2.0M | $1.7M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| ROE % | -67.9% | 382.2% | 90.9% | 50.2% | -80.1% | -557.5% | -97.7% | -124.3% | |
| ROA % | -58.1% | -58.7% | -151.4% | -431.5% | -60.9% | -340.1% | -82.3% | -117.0% | |
| ROIC % | -71.0% | -69.3% | -216.9% | 1324.6% | -62.3% | -542.7% | -99.9% | -159.9% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | |
| Operating Income | 0.0% | -9.7% | -28.8% | 5.8% | -10.2% | -99.4% | 27.8% | |
| Net Income | 0.0% | -13.9% | -32.6% | 4.0% | -39.0% | -54.4% | 28.7% | |
| EPS (Diluted) | 0.0% | -12.0% | -31.1% | 4.3% | 37.8% | 15.2% | 70.7% | |
| Operating Cash Flow | 0.0% | -21.6% | -27.1% | 19.8% | -31.5% | -111.2% | 39.3% | |
| Free Cash Flow | 0.0% | -21.6% | -27.1% | 19.8% | -31.5% | -111.2% | 39.3% | |
| R&D Expense | 0.0% | 13.8% | 16.0% | -12.4% | -6.7% | 119.3% | -35.4% | |
| SG&A Expense | 0.0% | -5.3% | 82.5% | 13.0% | 40.0% | 79.8% | -14.8% | |
| Total Assets | 0.0% | 12.7% | -48.6% | -66.3% | 884.3% | -72.3% | 194.8% | |
| Book Value / Share | 0.0% | -120.2% | -457.1% | -73.9% | 138.8% | -87.8% | 66.9% | |
| Debt | 0.0% | 91.1% | 370.9% | 91.7% | -96.5% | -12.7% | -20.3% | |
| Diluted Shares | 0.0% | 0.2% | 0.0% | 0.0% | 152.7% | 61.4% | 143.8% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.28
10Y Low / Med / High1.17 / 4.98 / 8.39
EV/EBITDA0.02
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$8.35
Tangible Book / Share
$2.35
Net Current Assets / Share
$2.54
Graham Net-Net
$1.80
Cash / Share
$2.61
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -3.77 | -3.37 | -2.57 | -2.68 | -6.21 | -1.50 | -1.20 | -0.69 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 2.63 | -13.04 | -2.34 | -1.35 | 4.98 | 8.39 | 1.17 | 1.28 | |
| EV/EBITDA | 56.50 | -1.91 | -2.30 | -3.21 | -5.67 | -1.35 | -0.18 | 0.02 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-13.15
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $3.0M | $351.0K | $52.4M |
| Net Income | -$4.7M | -$3.0M | -$4.4M |
| EPS | $-3.47 | $-2.25 | $-3.02 |
| # Analysts (EPS) | 3 | 2 | 3 |